

Press Release

Zug, 12 June 2012

Basilea enters into global agreement with Stiefel, a GlaxoSmithKline company, for Toctino® (alitretinoin)

Basilea announced today that it has entered into an exclusive worldwide agreement with Stiefel for Toctino®. Stiefel will assume worldwide responsibility for the development, manufacturing, commercialization, and distribution of the product. Basilea will receive a GBP 146 million (CHF 216 million) upfront payment and is eligible for additional milestone payments of up to GBP 50 million (CHF 74 million) and will also receive low double-digit participation from potential future Toctino® sales in the US.

HBM BioVentures holds about 2.4 million shares, almost 25% of the company, making it its largest shareholder.

About Basilea Pharmaceutica

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX:BSLN). Through the fully integrated research and development operations of its Swiss subsidiary Basilea Pharmaceutica International Ltd. the company focuses on innovative pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology, targeting the medical challenge of resistance and non-response to current treatment options in the hospital and specialty care setting.

For further information, please contact Dr. Andreas Wicki, CEO HBM BioVentures Ltd, tel.: +41 41 768 11 08, andreas.wicki@hbmbioventures.com.

Profile of HBM BioVentures AG

HBM BioVentures invests in the healthcare sector. The Company holds and manages an international portfolio of some twenty five promising companies in the biotechnology/human medicine, medical technology and diagnostics sectors. Many of these companies have their lead products already available on the market, or at an advanced stage of development. The focus of

NOT FOR DISTRIBUTION IN USA, CANADA, JAPAN OR AUSTRALIA

HBM BioVentures

investment is on follow-on financing for existing portfolio companies. These portfolio companies are closely tracked and actively guided on their strategic directions. This is what makes HBM BioVentures an interesting alternative to investing in big pharma and biotech companies. HBM BioVentures has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (Wertpapierprospektgesetz). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM BioVentures Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

HBM BioVentures Ltd

Bundesplatz 1 CH-6300 Zug | Tel: +41 41 768 11 08 | Fax: +41 41 768 11 09 | info@hbmbioventures.com
www.hbmbioventures.com